Vetmedin® world first in veterinary cardiology to be announced at the BSAVA Congress 9-12th April
A world first in veterinary cardiology will be announced at BSAVA Congress, 9 – 12 April 2015, from the makers of Vetmedin, Boehringer Ingelheim Vetmedica.
Proven to extend survival and improve quality of life in dogs with congestive heart failure, Vetmedin will be communicating the exciting results of a ground-breaking study to vets and industry in a series of announcements and activities taking place at the Congress.
The news could have the potential to extend the lives of thousands of Doberman Pinschers who are prone to developing Dilated Cardiomyopathy.
Approximately 25 – 50% of Dobermans develop DCM in their lifetime, with sudden death of around 25 – 30% of those affected, before showing any clinical signs of heart failure. Even with optimal treatment, once heart failure develops the survival times are typically short at just 2 – 4 months.
The PROTECTstudy is the first prospective, blinded study in veterinary cardiology of its kind to demonstrate a significant benefit of treating dogs in the pre-clinical phase of DCM. To find out more, veterinary professionals should visit the Vetmedin stand, 431, where more information will be available.
During the Congress, there will also be the opportunity to enter a photography competition to win a series of prizes, which will increase in value as the number of entries rises. Vets will be encouraged to re-evaluate their approach to pre-clinical DCM.
Boehinger Ingelheim is committed to ensuring veterinarians can provide their patients with the latest advancements in cardiac care via its dedicated and continued investment.